Safety analysis
ADVERSE EVENTS
The safety analysis set included all randomised patients who received at least one injection of either study product (IMP or comparator), regardless of any protocol deviations. All potential adverse events (AEs) described for the 2 radiopharmaceuticals were collected from the time of the injection up to 24 h and they were all documented. For a detailed description, see Supplemental file 